Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration

PINK1 import regulation; a fine system to convey mitochondrial stress to the cytosol

(2018) Shiori Sekine et al.   BMC BIOLOGY

A small molecule inhibitor of Rheb selectively targets mTORC1 signaling

(2018) Sarah J. Mahoney et al.   Nature Communications

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis

(2018) Dilan Athauda et al.   Journal of Parkinsons Disease

Therapeutic approaches to target alpha-synuclein pathology

(2017) Patrik Brundin et al.   EXPERIMENTAL NEUROLOGY

Targeting LRRK2 in Parkinson’s disease: an update on recent developments

(2017) Sharon L. Chan et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis

(2017) Kyle S. McCommis et al.   HEPATOLOGY

Inhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death

(2017) Ajit S. Divakaruni et al.   JOURNAL OF CELL BIOLOGY

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

(2017) Dilan Athauda et al.   LANCET

Glitazone use associated with reduced risk of Parkinson's disease

(2017) Brage Brakedal et al.   MOVEMENT DISORDERS

The two-century journey of Parkinson disease research

(2017) Serge Przedborski   NATURE REVIEWS NEUROSCIENCE

mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate

(2017) Andrea L. Marat et al.   SCIENCE

The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling

(2017) Mee-Sup Yoon   Nutrients

Implications of DNA Methylation in Parkinson’s Disease

(2017) Ernesto Miranda-Morales et al.   Frontiers in Molecular Neuroscience

Genetics of Parkinson's disease

(2016) Christina M. Lill   MOLECULAR AND CELLULAR PROBES

Pioglitazone ameliorates the phenotype of a novel Parkinson’s disease mouse model by reducing neuroinflammation

(2016) Milena Pinto et al.   Molecular Neurodegeneration

Defects in trafficking bridge Parkinson's disease pathology and genetics

(2016) Asa Abeliovich et al.   NATURE

A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance

(2016) Cholsoon Jang et al.   NATURE MEDICINE

The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis

(2016) Lauren Hirsch et al.   NEUROEPIDEMIOLOGY

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

(2016) Walter N. Kernan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic susceptibility variants in parkinsonism

(2016) Alexandra I. Soto-Ortolaza et al.   PARKINSONISM & RELATED DISORDERS

Insulin resistance and Parkinson’s disease: A new target for disease modification?

(2016) D. Athauda et al.   PROGRESS IN NEUROBIOLOGY

How neuroinflammation contributes to neurodegeneration

(2016) R. M. Ransohoff   SCIENCE

The Warburg Effect: How Does it Benefit Cancer Cells?

(2016) Maria V. Liberti et al.   TRENDS IN BIOCHEMICAL SCIENCES

Thiazolidinediones and Parkinson Disease: A Cohort Study

(2015) John G. Connolly et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Effect of pioglitazone medication on the incidence of dementia

(2015) Michael T. Heneka et al.   ANNALS OF NEUROLOGY

Mitochondrial pyruvate transport: a historical perspective and future research directions

(2015) Kyle S. McCommis et al.   BIOCHEMICAL JOURNAL

The genetics of Parkinson's disease

(2015) Stephen Mullin et al.   BRITISH MEDICAL BULLETIN

Hepatic Mitochondrial Pyruvate Carrier 1 Is Required for Efficient Regulation of Gluconeogenesis and Whole-Body Glucose Homeostasis

(2015) Lawrence R. Gray et al.   Cell Metabolism

Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling

(2015) Kyle S. McCommis et al.   Cell Metabolism

Mitochondrial pyruvate import and its effects on homeostasis

(2015) Benoît Vanderperre et al.   CURRENT OPINION IN CELL BIOLOGY

Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT

(2015) M. A. Abdul-Ghani et al.   DIABETES OBESITY & METABOLISM

Regulation of mitochondrial pyruvate uptake by alternative pyruvate carrier complexes

(2015) T. Bender et al.   EMBO JOURNAL

The TZD insulin sensitizer clue provides a new route into diabetes drug discovery

(2015) Jerry R. Colca   Expert Opinion on Drug Discovery

Parkinson's disease

(2015) Lorraine V Kalia et al.   LANCET

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

(2015)   LANCET NEUROLOGY

Monitoring Mitochondrial Pyruvate Carrier Activity in Real Time Using a BRET-Based Biosensor: Investigation of the Warburg Effect

(2015) Vincent Compan et al.   MOLECULAR CELL

Alpha-synuclein propagation: New insights from animal models

(2015) Benjamin Dehay et al.   MOVEMENT DISORDERS

Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone

(2015) Diogo Mendes et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

(2015) Iciar Aviles-Olmos et al.   Journal of Parkinsons Disease

Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study

(2015) Ruth Brauer et al.   PLOS MEDICINE

Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes

(2014) Raymond E. Soccio et al.   Cell Metabolism

Glutamine Oxidation Maintains the TCA Cycle and Cell Survival during Impaired Mitochondrial Pyruvate Transport

(2014) Chendong Yang et al.   MOLECULAR CELL

Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier

(2014) Nathaniel M. Vacanti et al.   MOLECULAR CELL

Branched-chain amino acids in metabolic signalling and insulin resistance

(2014) Christopher J. Lynch et al.   Nature Reviews Endocrinology

Mitochondrial Pyruvate Carrier 2 Hypomorphism in Mice Leads to Defects in Glucose-Stimulated Insulin Secretion

(2014) Patrick A. Vigueira et al.   Cell Reports

Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment

(2013) Daniel Lindqvist et al.   BRAIN BEHAVIOR AND IMMUNITY

Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases

(2013) Jerry R Colca et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Inhibition of Mitochondrial Pyruvate Transport by Zaprinast Causes Massive Accumulation of Aspartate at the Expense of Glutamate in the Retina

(2013) Jianhai Du et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Exenatide and the treatment of patients with Parkinson’s disease

(2013) Iciar Aviles-Olmos et al.   JOURNAL OF CLINICAL INVESTIGATION

Advances in the genetics of Parkinson disease

(2013) Joanne Trinh et al.   Nature Reviews Neurology

Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins

(2013) Jerry R. Colca et al.   PLoS One

Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier

(2013) A. S. Divakaruni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease

(2013) Eugene Chang et al.   Journal of Diabetes Investigation

New Agents Promote Neuroprotection in Parkinson’s Disease Models

(2012) Claudia Maria Miranda Santos   CNS & Neurological Disorders-Drug Targets

Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: Implications for Parkinson’s disease

(2012) Almas Siddiqui et al.   FREE RADICAL BIOLOGY AND MEDICINE

Insulin Resistance and Metabolic Derangements in Obese Mice Are Ameliorated by a Novel Peroxisome Proliferator-activated Receptor γ-sparing Thiazolidinedione

(2012) Zhouji Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum

(2012) Daniel Lindqvist et al.   PLoS One

Identification and Functional Expression of the Mitochondrial Pyruvate Carrier

(2012) S. Herzig et al.   SCIENCE

A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans

(2012) D. K. Bricker et al.   SCIENCE

PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease

(2011) Joo-Ho Shin et al.   CELL

Diabetes and Risk of Parkinson's Disease: A systematic review and meta-analysis

(2011) E. Cereda et al.   DIABETES CARE

Fighting neurodegeneration with rapamycin: mechanistic insights

(2011) Jordi Bové et al.   NATURE REVIEWS NEUROSCIENCE

PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy

(2010) Noriyuki Matsuda et al.   JOURNAL OF CELL BIOLOGY

Parkin-induced mitophagy in the pathogenesis of Parkinson disease

(2009) Derek Narendra et al.   Autophagy

PINK1-dependent recruitment of Parkin to mitochondria in mitophagy

(2009) C. Vives-Bauza et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy

(2008) Wolfgang C. Winkelmayer et al.   ARCHIVES OF INTERNAL MEDICINE